DelMar Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, DMPI, DelMar Pharmaceuticals Inc, priceseries

DelMar Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
2.00
Close
1.90
High
2.00
Low
1.86
Previous Close
1.87
Daily Price Gain
0.03
YTD High
136.00
YTD High Date
Feb 27, 2013
YTD Low
0.38
YTD Low Date
Mar 26, 2020
YTD Price Change
-66.50
YTD Gain
-97.22%
52 Week High
2.00
52 Week High Date
Jan 28, 2021
52 Week Low
1.86
52 Week Low Date
Jan 28, 2021
52 Week Price Change
0.00
52 Week Gain
0.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 25. 2017
39.00
Feb 9. 2017
46.10
11 Trading Days
18.20%
Link
LONG
Oct 30. 2017
8.89
Oct 31. 2017
9.55
1 Trading Days
7.37%
Link
LONG
Dec 28. 2017
10.60
Jan 17. 2018
14.29
12 Trading Days
34.80%
Link
LONG
Sep 7. 2018
5.60
Sep 27. 2018
7.53
14 Trading Days
34.59%
Link
LONG
Jan 4. 2019
3.60
Jan 10. 2019
3.85
4 Trading Days
6.96%
Link
LONG
Mar 15. 2019
3.39
Mar 28. 2019
4.65
9 Trading Days
37.16%
Link
LONG
Aug 8. 2019
1.61
Aug 13. 2019
2.03
3 Trading Days
26.09%
Link
LONG
Jul 17. 2020
0.88
Jul 24. 2020
0.98
5 Trading Days
11.36%
Link
LONG
Sep 8. 2020
1.36
Sep 17. 2020
1.51
7 Trading Days
10.82%
Link
Company Information
Stock Symbol
DMPI
Exchange
NasdaqCM
Company URL
http://www.delmarpharma.com
Company Phone
-
CEO
Jeffrey A. Bacha
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
-
About

DelMar Pharmaceuticals, Inc. is a clinical and commercial stage drug development company, which focuses on the research and development of drugs for the treatment of cancer. It offers VAL-083; drug discovery research; as well as patents and intellectual property. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in Vancouver, Canada.

Description

DelMar Pharmaceuticals, Inc., a clinical stage company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity in patients with glioblastoma multiforme, a form of brain cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China; and collaboration with the University of Texas MD Anderson Cancer Center. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading